Seed · Biotech · Malmo, Sweden · Founded 2020 · 5–15 employees
Strike Pharma has developed the proprietary ADAC (Adaptable Drug Affinity Conjugate) technology platform for precision immunotherapy, enabling targeted delivery of nanoparticles to specific cells for in vivo CAR-T therapy. The technology allows for truly individualized cancer treatments based on each patient's genetic profile, potentially reducing side effects while increasing therapeutic efficacy. The company has raised approximately €5.4M across two rounds and moved operations from Uppsala to the SmiLe Venture Hub in Lund in 2025. Their approach to in vivo CAR-T is considered highly promising in cancer immunotherapy, with potential applications across multiple disease areas including autoimmune diseases.
No open roles listed right now.